A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies

This study is designed for adults aged 18 to 74 years old. To join, you must have a confirmed genetic diagnosis of a Type 1 Interferonopathy, such as Aicardi-Goutières syndrome (AGS), COPA syndrome, or Familial chilblain lupus. Your doctor will need to confirm the specific genetic change related to your condition.

You can participate whether you are currently receiving standard treatment for your condition, as long as it's at a stable dose, or if you are not on specific treatment. If you are a woman who could become pregnant, you must agree to use highly effective birth control methods during the study. Similarly, men in the study whose partners could become pregnant must also use effective contraception.

However, you won't be able to join if you have a major ongoing inflammatory or connective tissue disease other than a Type 1 Interferonopathy, or if your doctor believes you have a high risk of infections. Also, if there are signs of moderate to severe kidney problems, you would not be eligible.

If you join the study, you'll start by taking a lower dose of BI 3000202 tablets every day for four weeks. After this, you'll switch to a higher dose of the tablets and continue taking them for an additional 36 weeks. You might continue receiving the study medicine for longer, until all participants have completed 40 weeks of treatment (which is about 9 months).

During the study, you will have regular check-ups at the study site. This will involve at least 13 visits, but potentially more, depending on when you start. These visits are important for the doctors to monitor your health, check how your body is responding to the medicine, and record any new symptoms or health problems you might experience. You may also continue your usual treatments for your condition alongside the study medicine.